Regenxbio (RGNX) Stock Price
Regenxbio Price
Regenxbio (RGNX) Stock | ISIN US75901B1070 | WKN A140E0. The current Regenxbio stock price is 6.86 USD (2026). Revenue is 255.74 M USD. Net income is -138.03 M USD. The P/E ratio is -2.56. Market capitalization is 353.53 M USD. Regenxbio operates in the Health sector.
Revenue has compounded at 32% per year over the past 12 years to 170.44 M USD. Regenxbio's net margin stands at -113.8%, down from 27.2% several years earlier.
Regenxbio stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Regenxbio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Regenxbio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Regenxbio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Regenxbio Price |
|---|
Regenxbio Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Regenxbio Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 0.08 | 0.17 | 0.26 | 0.32 | 0.47 | 0.68 | 0.88 | 1.13 |
| -7.78 | 104.82 | 50 | 23.53 | 47.94 | 45.92 | 29.41 | 28.18 |
| 59.04 | 88.24 | 58.82 | 47.62 | 32.19 | 22.06 | 17.05 | 13.3 |
| 49 | 150 | 150 | 150 | 150 | 150 | 150 | 150 |
| -227 | -193 | -138 | -105 | -78 | 29 | 203 | 441 |
| -13.69 | -14.98 | -28.5 | -23.91 | -25.71 | -137.18 | 600 | 117.24 |
| 49.51 | 51.57 | 51.57 | 51.57 | 51.57 | 51.57 | 51.57 | 51.57 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Regenxbio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Regenxbio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Regenxbio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Regenxbio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Regenxbio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Regenxbio stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Regenxbio Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Regenxbio business model & stock analysis
Regenxbio SWOT Analysis
Strengths
Regenxbio Inc has a strong portfolio of gene therapy products that have shown promising results in clinical trials. This positions the company as a leader in the field of gene therapy.
The company has a highly talented team of scientists and researchers who possess extensive expertise in gene therapy, giving them a competitive advantage in developing innovative treatments.
Regenxbio Inc has formed strategic partnerships with major pharmaceutical companies, providing them with access to additional resources, expertise, and potential distribution channels.
Weaknesses
One weakness of Regenxbio Inc is its heavy reliance on a limited number of product candidates. If any of these candidates fail in clinical trials or face regulatory hurdles, it could significantly impact the company's revenue and future prospects.
The company's success heavily depends on the regulatory environment for gene therapy, which is subject to change and uncertainty. This poses a risk to the company's ability to bring its products to market.
Opportunities
The growing demand for effective treatments in genetic diseases presents a significant opportunity for Regenxbio Inc. As the field of gene therapy continues to advance, the company has an opportunity to capture a larger market share.
Expanding partnerships within the healthcare industry can open doors for collaborative research and development, allowing Regenxbio Inc to access new technologies and potential markets.
Threats
One major threat to Regenxbio Inc is the intense competition in the gene therapy market. Other companies are also investing heavily in research and development, potentially resulting in similar or superior gene therapy products.
Uncertainty surrounding intellectual property rights and potential legal disputes pose a threat to the company's ability to protect and monetize its gene therapy technologies and products.
Regenxbio Segments
Regenxbio Revenue by Segment (1/3)
3 Years
5 Years
Max
Details
Regenxbio Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Regenxbio Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Regenxbio Eulerpool Fair Value
Regenxbio historical P/E ratio, EBIT multiple, and P/S ratio
Regenxbio annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Regenxbio shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Regenxbio Earnings Estimates
Regenxbio Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/14/2026 | -1.37USD | 26.85 MUSD | 2026 Q1 |
| 5/11/2026 | -1.37USD | 26.85 MUSD | 2026 Q1 |
| 5/6/2026 | -1.37USD | 26.85 MUSD | 2026 Q1 |
| 3/5/2026 | -0.82USD | 47.29 MUSD | 2025 Q4 |
| 3/3/2026 | -0.82USD | 47.29 MUSD | 2025 Q4 |
| 8/7/2025 | -1.12USD | 28.67 MUSD | 2025 Q2 |
| 11/6/2024 | -1.14USD | 23.89 MUSD | 2024 Q3 |
| 5/1/2024 | -1.31USD | 23.98 MUSD | 2024 Q1 |
| 2/26/2024 | -1.23USD | 36.81 MUSD | 2023 Q4 |
| 8/1/2023 | -1.55USD | 34.63 MUSD | 2023 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Regenxbio stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Regenxbio shareholder structure
| % | Name |
|---|---|
8.47111% | |
7.73899% | |
6.54245% | |
5.62604% | |
4.91199% | |
4.43398% | |
3.37769% | |
2.95655% | |
2.64084% | |
2.3268% |
Regenxbio Executives and Management Board
Mr. Kenneth Mills
(50)Chairman of the Board · since 2009
Mr. Curran Simpson
(63)President, Chief Executive Officer, Director · since 2015
Mr. Mitchell Chan
(44)Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Dr. Olivier Danos
(67)Executive Vice President, Chief Scientific Officer
Mr. Patrick Christmas
(54)Executive Vice President, Chief Strategy and Legal Officer
Regenxbio Supply Chain
Frequently asked questions about Regenxbio
The business model of Regenxbio Inc is focused on developing and commercializing gene therapy treatments for various genetic diseases. Regenxbio utilizes its proprietary adeno-associated virus (AAV) gene delivery platform, which enables targeted and precise gene therapy delivery to specific cells in the body. This versatile platform allows Regenxbio to address a wide range of genetic disorders, including neurodegenerative diseases, metabolic disorders, and ophthalmic diseases. By leveraging their expertise in gene therapy and collaborating with partners, Regenxbio aims to bring effective and innovative treatments to patients with unmet medical needs.
Regenxbio stock
Regenxbio Peer Group
Regenxbio Ticker
Regenxbio FIGI
All fundamentals and in-depth analysis of Regenxbio
Our stock analysis for Regenxbio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regenxbio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.